Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $27.9 million.

  • Dare Bioscience's Total Liabilities rose 4271.23% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year increase of 4271.23%. This contributed to the annual value of $28.1 million for FY2024, which is 677.32% up from last year.
  • According to the latest figures from Q3 2025, Dare Bioscience's Total Liabilities is $27.9 million, which was up 4271.23% from $25.7 million recorded in Q2 2025.
  • Over the past 5 years, Dare Bioscience's Total Liabilities peaked at $32.7 million during Q4 2022, and registered a low of $7.1 million during Q2 2021.
  • For the 5-year period, Dare Bioscience's Total Liabilities averaged around $22.2 million, with its median value being $24.0 million (2022).
  • As far as peak fluctuations go, Dare Bioscience's Total Liabilities skyrocketed by 15939.29% in 2022, and later tumbled by 2852.49% in 2024.
  • Over the past 5 years, Dare Bioscience's Total Liabilities (Quarter) stood at $17.1 million in 2021, then soared by 91.84% to $32.7 million in 2022, then dropped by 19.52% to $26.3 million in 2023, then grew by 6.77% to $28.1 million in 2024, then dropped by 0.79% to $27.9 million in 2025.
  • Its Total Liabilities was $27.9 million in Q3 2025, compared to $25.7 million in Q2 2025 and $28.2 million in Q1 2025.